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Introduction
In 2014, the ‘ice bucket challenge’ raised over $140 mil-
lion worldwide for research into amyotrophic lateral scle-
rosis (ALS). This unprecedented boost to research funding
is now beginning to deliver significant advances in our
understanding of the pathogenesis of this devastating dis-
ease, and all the studies in this month’s journal club were,
at least in part, funded by charitable organisations that
benefited from these monies.
The first paper we discuss reports the results of the
largest genetic study of ALS to date, with discovery of
three new genes associated with ALS by utilising novel
whole-genome sequencing technology. Importantly, the
study also illuminates the genetic architecture of ALS,
which in turn is likely to inform design of future genetic
studies and suggests opportunities for clinical research to
establish genotype–phenotype correlations. However, as
genetic studies of rapidly increasing power reveal
increasing numbers of risk variants and mutations, the next
substantial challenge is to understand how such variants
cause disease. The second and third papers discussed this
month report on attempts to understand how two leading
ALS risk variants cause disease and may provide exciting
avenues for the development of novel therapeutic agents.
The association of the C9orf72 repeat expansion with ALS,
reviewed in journal club in 2012 and 2015, is now well
documented and Kramer et al. report notable progress in
translating our understanding into novel therapeutic targets.
Similarly, Ito et al. report that mutations in the established
ALS risk gene optineurin may function by sensitising cells
to a form of regulated cell death, which could again be
targeted for therapeutic intervention.
Genome-wide association analyses identify new
risk variants and the genetic architecture
of amyotrophic lateral sclerosis
Genetic sequencing technology is advancing at a consid-
erable pace, and learning how to effectively harness the
power of whole-genome sequencing will provide infor-
mation of unparalleled depth and detail. Van Rheenen et al.
used whole-genome sequencing data on 1246 ALS cases
and 615 controls to dramatically improve the sensitivity of
genetic screening to enable detection of low-frequency
variants by imputation. An impressive 8.7 million SNPs
were genotyped in 7763 ALS cases and 4669 controls, and
by combining with genotyping data from 41 other genetic
studies of ALS, a meta-analysis was performed on a total of
12,577 ALS cases and 23,475 controls. The study reports
three new independent loci that associate with ALS risk
with genome-wide significance: C27orf2, MOBP and
SCFD1, which were all replicated in subsequent analysis of
2579 ALS cases and 2767 controls. Three previously
associated loci were also replicated: C9orf72, SARM1 and
UNC13A.
The authors go on to report fine mapping and functional
data that begin to explain how the newly discovered vari-
ants confer risk to ALS. Fine mapping of C27orf2 in 2562
ALS cases and 1138 controls demonstrated an excess of
loss-of-function mutations, suggesting pathology is caused
by reduced protein product of C27orf2. Also, publicly
available gene expression data from human brain were
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used to search for SNPs at the risk loci that correlate with
expression of nearby genes. This analysis revealed that the
variants at SARM1 and UNC13A appear to, at least partly,
influence function by controlling expression of the genes
POLDIP2 and KCNN1, respectively.
Finally, the study proceeded to analyse the genetic
architecture of ALS by estimating the proportion of heri-
tability explained by low versus high frequency variants.
When compared with schizophrenia, a classical polygenic
disorder dominated by common variants, the genetic risk
for ALS appears to be dominated by a large number of rare
variants that each confer substantial risk.
Comment This powerful study identifies three new loci
that confer risk to ALS and provides some initial infor-
mation on the possible pathogenic mechanisms. This is by
far the largest genetic study in ALS to date and goes some
way to resolving a fundamental question about the genetic
architecture of ALS. Complementary to this work is a study
published in the same edition of Nature Genetics by Kenna
et al. who report discovery of a new gene implicated in
familial ALS by exome sequencing. As a substantial pro-
portion of the heritability of ALS is conferred by a large
number of rare variants, each conferring relatively high risk
to disease, future genetic studies of ALS must ensure that
rare variants are captured. Such a genetic architecture
implies that clinicians will have a key role in establishing
genotype–phenotype correlations, which will help deter-
mine how genetic factors contribute to clinical
heterogeneity.
Van Rheenen W et al. (2016) Nature Genetics
48(9):1043–1046.
Spt4 selectively regulates the expression of C9orf72
sense and antisense mutant transcripts
Expansions of the hexanucleotide repeat within the
C9orf72 gene are the leading genetic cause of ALS, being
responsible for 7–10 % cases of sporadic ALS and 40 % of
familial cases. In a previous journal club earlier this year,
we discussed a paper that explored the effect of regulation
of C9orf72 on clinical outcomes, which added to the data
suggesting that the expansion caused a pathological gain-
of-function. Kramer and colleagues go further in this paper
by identifying a potential therapeutic avenue based on
reducing the expression of C9orf72. Work in Huntington’s
disease (HD) and on C9orf72 suggests two major mecha-
nisms by which such expansions can cause disease: RNA
toxicity by aggregation of RNA transcribed from the
repeats into intracellular foci that disrupt cellular machin-
ery, and protein toxicity by aberrant translation of the
repeat mRNA into toxic dipeptide repeat proteins (DPRs).
The authors hypothesise that Spt4, a transcription factor
recently discovered to mediate transcription of long repeat
sequences in HD, could be involved in transcription of the
pathological hexanucleotide repeat expansion in C9orf72.
The study generated three models with the pathological
expansion (yeast, C. elegans and Drosophila) and found
that deleting or knocking down Spt4 reduced or eradicated
RNA foci aggregation and DPR production.
The experiment was repeated in human fibroblasts
isolated from ALS cases with (c9ALS) and without the
C9orf72 repeat expansion and healthy controls and
detected foci of sense and antisense expansion RNA
strands and DPR proteins exclusively in c9ALS fibrob-
lasts. Using RNA interference to knock down the
mammalian version of Spt4 resulted in decreased
C9orf72 mRNA and PDR proteins, and reduced sense
and antisense RNA foci. This effect was partially
replicated in human cortical neurons generated from
induced pluripotent stem cells.
Comment This study illustrates how results from genetic
studies can begin to be translated into therapeutic targets.
Whilst the mechanism of toxicity of the C9orf72 expansion
has not been confirmed, it is likely that treatments capable
of reducing its expression will be beneficial. Targeting
transcription apparatus can produce far-reaching effects on
other genes, but this study also reported that the effect of
reducing the expression of Spt4 had minimal effects on the
expression of other genes using RNA sequencing, sug-
gesting that this could be a relatively specific therapeutic
target.
Kramer NJ et al. (2016) Science 353(6300):708–12.
RIPK1mediates axonal degeneration by promoting
inflammation and necroptosis in ALS
Optineurin is a gene that has an established association
with familial ALS, but the pathogenic mechanism is
unclear. In this paper, Ito et al. report that one mechanism
appears to be sensitising cells to a form of regulated cell
death called necroptosis through the activity of the enzyme
RIPK1.
The authors generated a mouse model with homozygous
deletions of optineurin, which developed a progressive
degenerative motor neuropathy and spinal cord
histopathology similar to ALS. Mice that were also gen-
erated to be homozygous for inactivated RIPK1 displayed
reversed spinal cord pathology and motor dysfunction.
Several different types of mouse cells including
embryonic fibroblasts, adipose cells, cultured oligoden-
drocytes and spinal cord samples were subject to opti-
neurin deletions or knockdowns and displayed evidence of
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increased mediators of necroptosis including RIPK1.
Interestingly, cultured oligodendrocytes homozygous for
optineurin deletions underwent significantly greater cell
death and this was reversed in cells also homozygous for
RIPK1 deletions or by giving an inhibitor of necroptosis
(Nec-1s). In addition, microglia homozygous for optineurin
deletions had increased levels of RIPK1 activation and
acquired a proinflammatory phenotype.
The study then investigated whether the mechanism is
generalisable by investigating the SOD1 mouse model.
Markers of necroptosis were found to be raised in spinal
cord samples and the mouse displayed a similar motor
deficit, and both were reversed by administration of Nec-
1s. Finally, analysis of spinal cord samples from human
sporadic ALS cases revealed increased markers of
necroptosis in microglia and oligodendrocytes.
Comment By investigating the functional consequences
of mutations of an established risk gene, this work pro-
vides the first evidence that necroptosis may be an
important pathological mechanism in ALS that could be
targeted for therapeutic intervention. Interestingly, the
mechanism appears to be more important in oligoden-
drocytes and microglia rather than neurons, which sug-
gests that cells other than neurons may mediate at least
part of the neurodegenerative process. Before pursuing
potential therapeutic agents targeting necroptosis, how-
ever, further work in human cells is necessary to deter-
mine its role in neurodegeneration in familial and
sporadic forms of ALS.
Ito Y et al. (2016) Science 353(6299):603–8.
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